Rova-T kills SCLC TICs by targeting DLL3.5 We observed a higher expression of DLL3 in TICs of H82 and H526 compared to non-TICs (Supplementary Fig. 1A–C), and treatment with CBL had no effect on DLL3 expression in TICs (Supplementary Fig. 1D), suggesting that CBL does not interfere with Rova-T efficacy by decreasing DLL3 levels. Here, CBL is linked to small cell lung carcinoma.